The tools to detect serious disease years before symptoms appear already exist. What we are waiting on is a health care system structured to use them. Early in my career in primary care, I watched patients with vague symptoms and normal lab results get dismissed as anxious or mildly depressed. While some were, others were experiencing the very earliest stages of disease. Signals that more advanced diagnostics would have caught, years before a harder conversation became necessary. That gap between what science could see and what standard care was structured to look for stayed with me. It still does. Because despite enormous advances in precision medicine, genomics, and early detection technology, that gap has not meaningfully closed for most patients.
A system optimized for sick care
Research suggests the lag between clear scientific evidence and widespread clinical adoption can be as long as 15 to 20 years. That delay is not simply organizational inertia. It is structural. A system built around high patient throughput, generalized protocols, and reactive response to symptoms is not designed for the kind of sustained, individualized attention that prevention requires. The consequences are measurable. Today, the average American spends 12.4 years in poor health at the end of life. We have normalized this decade of diminished vitality, treating it as an inevitable feature of aging rather than a preventable outcome. But noncommunicable diseases do not appear overnight. They are the result of long, subtle physiological shifts that begin well before any signs or symptoms emerge. We have had the science to detect many of these shifts for years. What we have lacked is a clinical model built to act on that science proactively.
Studies suggest that traditional preventive care like annual physicals and standard screenings may miss up to 40 percent of diseases in asymptomatic individuals. By the time cardiovascular disease, metabolic disorders, cancer, or neurodegeneration are detected through conventional means, options are more limited and prognosis less favorable. This is not a failure of individual clinicians. It is a failure of system design.
What closing the gap actually requires
Bridging the distance between emerging science and clinical practice requires two things that our current system struggles to deliver: multimodal personalization and clinician support.
- On personalization: We need to move beyond our reliance on population-wide averages and single-point diagnostics. No single test provides a complete picture, and the risk of both false positives and false negatives is real. A dynamic approach that integrates data from genomics, advanced blood panels, imaging, wearables, and microbiome analysis creates a more cohesive clinical picture and allows for a highly individualized risk profile, one that changes as the patient changes, tracked against their own biological baseline over time.
- On clinician support: Today’s physicians are already stretched thin by high patient loads and considerable administrative burden. They cannot reasonably be expected to evaluate every new research study, vetting which diagnostics are scientifically sound, which are real but not yet clinically ready, and which can be responsibly implemented today. That is not a failure of curiosity or commitment. It is simply not what clinical practice is designed to do.
What clinicians need is not more data. They need that data interpreted, prioritized, and delivered with clearly actionable insight. Precision tools should not replace the physician-patient relationship. They should strengthen it, by giving clinicians the information needed to offer relevant, practical guidance.
Evidence as a prerequisite, not a preference
This is where the distinction between precision medicine done responsibly and the broader wellness industry matters most. There is no shortage of companies offering advanced diagnostics and personalized health insights. The more important question is how rigorously those tools have been evaluated before they reach a patient. The process of systematically identifying technologies proven effective in detecting disease risk and translating them into individualized, science-based care is what responsible concierge science looks like in practice. It is not a luxury model. It is a proof of concept for what prevention-focused care can look like when given the infrastructure to function properly.
The question we should be asking
Our goal as clinicians has always been to help patients live well, not just longer. Modern science has given us more tools to do that than at any point in history. The question is no longer whether early detection and personalized prevention are scientifically possible. They are. The clinicians I work with want to offer their patients more. What stands in the way is rarely will, but rather time, bandwidth, and a system that was never designed to support the kind of sustained, individualized attention prevention requires. What they need is a partner equipped to do that work alongside them, and to translate it into something actionable at the point of care. That is the gap precision medicine was always meant to close.
Julie Chen is a physician executive.
